Current Report Filing (8-k)
11 November 2022 - 08:16AM
Edgar (US Regulatory)
false 0001832038 0001832038 2022-11-10
2022-11-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): November 10,
2022
Invivyd, Inc.
(Exact Name of Registrant as Specified in its Charter)
|
|
|
|
|
Delaware |
|
001-40703 |
|
85-1403134 |
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
1601 Trapelo Road, Suite 178
Waltham, MA
|
|
02451 |
(Address of Principal Executive
Offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (781)
819-0080
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the
Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common stock, par value $0.0001 per
share |
|
IVVD |
|
The Nasdaq Stock Market
LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this
chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 2.02. |
Results of Operations and Financial Condition.
|
On November 10, 2022, Invivyd, Inc. (the “Company”) issued a
press release providing a corporate update and announcing its
financial results for the quarter ended September 30, 2022. A
copy of the press release is being furnished as Exhibit 99.1 to
this Current Report on Form 8-K and is incorporated by reference to
this Item 2.02.
The information furnished pursuant to this Item 2.02, including the
attached Exhibit 99.1, shall not be deemed to be “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934
(the “Exchange Act”) or otherwise subject to the liabilities of
that Section, nor shall it be deemed to be incorporated by
reference into any of the Company’s filings with the Securities and
Exchange Commission under the Exchange Act or the Securities Act of
1933, as amended, whether made before or after the date hereof,
regardless of any general incorporation language in such a filing,
except as expressly set forth by specific reference in such a
filing.
Item 9.01. |
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, as amended, the registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly
authorized.
|
|
|
|
|
|
|
|
|
|
|
INVIVYD, INC. |
|
|
|
|
Date: November 10, 2022 |
|
|
|
By: |
|
/s/ Jill Andersen
|
|
|
|
|
|
|
Jill Andersen |
|
|
|
|
|
|
Chief Legal Officer and Corporate
Secretary |
Adagio Therapeutics (NASDAQ:ADGI)
Historical Stock Chart
From Mar 2023 to Mar 2023
Adagio Therapeutics (NASDAQ:ADGI)
Historical Stock Chart
From Mar 2022 to Mar 2023